Read
- Angelina Jolie stunt double sues News Corp over hacking
- Kanye West wins over critics with 'daring' new album 'Yeezus'
- Massachusetts police search NFL player's home in homicide probe: report
- Shares choppy, dollar steady as Fed meets
- Journalist who brought down U.S. general is killed in Los Angeles car crash
Reuters Photojournalism
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
The Afghan Army
The many faces of the Afghan National Army, which has taken over security of the country from NATO. Slideshow
Sponsored Links
Senate probes painkiller makers, allied groups
1 of 2. U.S. Senate Finance Committee Chairman Max Baucus (D-MT) arrives to meet with a bipartisan group of lawmakers and Vice President Joe Biden, to work on a legislative framework for comprehensive deficit reduction, at the Blair House in Washington May 10, 2011.
Credit: Reuters/Jonathan Ernst
WASHINGTON |
WASHINGTON (Reuters) - A Senate panel has launched a probe of possible links between three drugmakers and nonprofit medical groups that advocated for increasing the use of prescription painkillers, now the target of a nationwide law enforcement crackdown.
Senate Finance Committee Chairman Max Baucus, a Democrat, and the panel's leading Republican, Senator Chuck Grassley, said the drugmakers and allied groups could be behind dubious marketing practices that have coincided with a huge jump in deadly overdoses from painkillers known as opioids.
"These painkillers have an important role in health care when prescribed and used properly, but pushing misinformation on consumers to boost profits is not only wrong, it's dangerous," Baucus said in a statement.
Baucus and Grassley said they sent letters to drugmakers Johnson & Johnson's Janssen Pharmaceuticals unit, Endo Pharmaceuticals and Purdue Pharma and seven medical groups seeking documents about their financial connections.
Purdue Pharma and Janssen both issued statements saying they were reviewing the letters and would work with the committee. There was no immediate response from Endo Pharmaceuticals.
Lawmakers hope to find out if medical groups have promoted misleading information about the risks and benefits of opioid use while receiving financial support from manufacturers.
The Senate investigation comes at a time when federal, state and local law enforcement officials are coming to grips with a national epidemic involving the illicit use of prescription drugs. Their abuse has surpassed heroin and cocaine as a source of fatal overdoses.
Opioids were involved in 14,800 overdose deaths in 2008, more than cocaine and heroin combined, according to the U.S. Centers for Disease Control and Prevention.
A crackdown spearheaded by the U.S. Drug Enforcement Administration has included healthcare companies including two Florida pharmacies operated by CVS Caremark Corp. and a distribution facility owned by Cardinal Health Inc..
Privately owned Purdue Pharma is the maker of OxyContin. Endo manufactures Percocet. Both have been linked to addiction and overdoses.
"There is growing evidence pharmaceutical companies that manufacture and market opioids may be responsible, at least in part, for this evidence by promoting misleading information," Baucus and Grassley said in their letters.
One of the groups, the American Pain Foundation, posted a notice on its Web site saying its board of directors voted May 3 to dissolve the organization because of ongoing financial obligations.
The Senate probe follows an investigation by nonprofit news website ProPublica and The Washington Post, which found that the American Pain Foundation received 90 percent of its funding from the drug and medical device industry in 2010.
At the same time, it produced its guides for patients, policymakers and journalists that played down the risks of opioid painkillers and promoted the benefits.
(Editing by M.D. Golan)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Unless someone thinks that the Senators are hard-pressed to find things to do?





Follow Reuters